Companies › Kivu Bioscience
2 active drug programs in 2 registered trials: 2 Phase 1; Oncology; next expected readout Dec 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| KIVU-305 CEACAM5-directed antibody-drug conjugate | CEACAM5 | Phase 1 | Solid Tumors | Dec 2027 |
| KIVU-107 PTK7-directed antibody-drug conjugate | PTK7 | Phase 1 | Advance Solid Tumors | Mar 2028 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07545356 | KIVU-305 | Phase 1 | Solid Tumors | Oncology | Dec 2027 |
| NCT07229313 | KIVU-107 | Phase 1 | Advance Solid Tumors | Oncology | Mar 2028 |
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.